Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>Baseline tumor H-score levels for AXL positivity by best confirmed overall response per investigator assessment in expansion cohorts. (A) Cohort 3 (Q3W): melanoma with BRAF V600 mutation; (B) cohort 4 (Q3W): melanoma with BRAF V600 wild-type; (C) cohort 5 (Q3W): sarcoma; (D) cohort 6 (3Q4W)...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Daljnji autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Izdano: |
2025
|
| Teme: | |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Budi prvi tko komentira!